OctoPlus focuses on developing innovative drug delivery systems. Our platform technologies offer unique advantages for the development of single-shot vaccines, such as:

• Release of fully functional antigens from the delivery matrix
• Tailor-made pulsed or linear release profile
• A proven clinical safety profile
• Cost-effective manufacturing
• Ease of upscaling
• Consisting of a biocompatible and biodegradable matrix

OctoPlus is currently co-developing a single-shot Hepatitis B vaccine and a single-shot Japanese encephalitis vaccine. The Japanese encephalitis vaccine is a co-development project of OctoPlus together with Singapore-based vaccine company SingVax .